Skip to main content
SpringerLink
Log in

Sporadic Gastric Well-Differentiated Neuroendocrine Tumors Have a Higher Ki-67 Proliferative Index

  • Published:
Endocrine Pathology Aims and scope Submit manuscript

Abstract

Well-differentiated neuroendocrine tumor (WDNET) of the stomach can arise in three distinct clinical settings: (1) in association with autoimmune atrophic gastritis, (2) in association with multiple neuroendocrine neoplasia type I (MEN I) or Zollinger-Ellison syndrome (ZES), or (3) sporadic. The Ki-67 proliferative index (PI) in gastric WDNETs in these three distinct clinical settings has not been evaluated in detail. Forty-five gastric WNETs underwent polypectomy (n = 4), endoscopic mucosal resection (n = 12), and surgical resection (n = 29) between 1994 and 2015 were included. H&E slides from each case were reviewed, and Ki-67 immunostain was performed on one representative tumor block. Ki-67 PI was determined by quantitative Aperio image analysis software in areas of strongest nuclear labeling (“hot spots”), and correlated with underlying clinical and pathological features. Twenty-one patients were male and 24 female with a median age of 57 years (range, 30–80 years). Tumors were classified as type I (n = 17), type II (n = 6), and type III (n = 22) WDNETs. Types II and III showed more advanced TNM stage compared to type I (p = 0.02, overall). WHO grade based on Ki-67 PI was higher in type III WDNETs [grade 1 (G1), n = 3; grade 2 (G2), n = 15; and grade 3 (G3), n = 4] than in type I WDNETs [G1, n = 5; G2, n = 12] and in type II WDNETs [G1, n = 2; G2, n = 4] (p = 0.050, overall). Ki-67 PI was significantly higher in type III WDNETs (mean ± SD = 13.0 ± 13.3 %) than in non-sporadic (type I and II) WDNETs (mean ± SD = 5.3 ± 3.3 %; p = 0.015). There was no difference in Ki-67 PI between type I WDNETs (mean ± SD = 5.2 ± 3.5 %) and type II WDNETs (mean ± SD = 5.6 ± 3.1%; p = 0.817). Higher Ki-67 PI was associated with higher tumor T stage (p = 0.003) and also tended to be associated with lymph node metastasis (p = 0.071). In the Kaplan-Meier survival analysis, type I was associated with a significantly longer disease-free survival (DFS) time compared to type II (p = 0.018) or III (0.010). Also, the WHO G3 group had a significantly shorter DFS time than the WHO G1 (p = 0.020) or G2 (p = 0.007) group. Gastric WDNET is a heterogeneous disease entity encompassing three clinical subtypes—type I, type II, and type III—having their own distinct clinicopathologic characteristics and prognosis. Our results showed that sporadic (type III) WDNET had a significantly higher Ki-67 PI than non-sporadic cases (type I or II); increased PI was associated with higher tumor stage. We also described four type III cases of morphologically WD gastric NET with WHO grade 3 on the basis of Ki-67 PI.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Solcia E AR, Capella C, Klimstra DS, Kloppel G, Komminoth P, Rindi G (2010) Neuroendocrine neoplasms of the stomach. In: Bosman FT, Carneiro F, Hruban RH, Theise ND (eds) World Health Organization Classification of Tumours of the Digestive. System, 4th edn. International Agency for Research on Cancer press, Lyon, pp 64–68

  2. Rindi G, Luinetti O, Cornaggia M, Capella C, Solcia E (1993) Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: a clinicopathologic study. Gastroenterology 104 (4):994–1006

    Article  CAS  PubMed  Google Scholar 

  3. Williams ED, Sandler M (1963) The classification of carcinoid tum ours. Lancet 1 (7275):238–239

    Article  CAS  PubMed  Google Scholar 

  4. Capella C SE, Sobin LH, Arnold R (2000) Endocrine tumours of the stomach. In: Hamilton SR (ed) World Health Organization Classification of Tumours. Pathology & genetics of tumours of the digestive. system, 3rd edn. International Agency for Research on Cancer press, Lyon, pp 53–57

  5. Rindi G, Kloppel G, Alhman H, Caplin M, Couvelard A, de Herder WW, Erikssson B, Falchetti A, Falconi M, Komminoth P, Korner M, Lopes JM, McNicol AM, Nilsson O, Perren A, Scarpa A, Scoazec JY, Wiedenmann B (2006) TNM staging of foregut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch 449 (4):395–401. doi: 10.1007/s00428-006-0250-1

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Pape UF, Jann H, Muller-Nordhorn J, Bockelbrink A, Berndt U, Willich SN, Koch M, Rocken C, Rindi G, Wiedenmann B (2008) Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. Cancer 113 (2):256–265. doi: 10.1002/cncr.23549

    Article  PubMed  Google Scholar 

  7. La Rosa S, Inzani F, Vanoli A, Klersy C, Dainese L, Rindi G, Capella C, Bordi C, Solcia E (2011) Histologic characterization and improved prognostic evaluation of 209 gastric neuroendocrine neoplasms. Hum Pathol 42 (10):1373–1384. doi: 10.1016/j.humpath.2011.01.018

    Article  PubMed  Google Scholar 

  8. The American Joint Committee on Cancer (2010) The AJCC Cancer Staging Manual, 7th edn. Springer, New York

    Book  Google Scholar 

  9. Kunz PL (2015) Carcinoid and neuroendocrine tumors: building on success. J Clin Oncol 33 (16):1855–1863. doi:10.1200/jco.2014.60.2532

    Article  CAS  PubMed  Google Scholar 

  10. Kubota T, Ohyama S, Hiki N, Nunobe S, Yamamoto N, Yamaguchi T (2012) Endocrine carcinoma of the stomach: clinicopathological analysis of 27 surgically treated cases in a single institute. Gastric Cancer 15 (3):323–330. doi:10.1007/s10120-011-0122-5

    Article  PubMed  Google Scholar 

  11. Ozkara S, Aker F, Yesil A, Senates E, Canbey C, Yitik A, Gonen C (2013) Re-evaluation of cases with gastroenteropancreatic neuroendocrine tumors between 2004 and 2012 according to the 2010 criteria. Hepatogastroenterology 60 (127):1665–1672

    PubMed  Google Scholar 

  12. Pasaoglu E, Dursun N, Ozyalvacli G, Hacihasanoglu E, Behzatoglu K, Calay O (2015) Comparison of World Health Organization 2000/2004 and World Health Organization 2010 classifications for gastrointestinal and pancreatic neuroendocrine tumors. Ann Diagn Pathol 19 (2):81–87. doi:10.1016/j.anndiagpath.2015.01.001

    Article  PubMed  Google Scholar 

  13. Yang Z, Tang LH, Klimstra DS (2013) Gastroenteropancreatic neuroendocrine neoplasms: historical context and current issues. Semin Diagn Pathol 30 (3):186–196. doi:10.1053/j.semdp.2013.06.005

    Article  PubMed  Google Scholar 

  14. Rindi G, Azzoni C, La Rosa S, Klersy C, Paolotti D, Rappel S, Stolte M, Capella C, Bordi C, Solcia E (1999) ECL cell tumor and poorly differentiated endocrine carcinoma of the stomach: prognostic evaluation by pathological analysis. Gastroenterology 116 (3):532–542

    Article  CAS  PubMed  Google Scholar 

  15. Higham AD, Bishop LA, Dimaline R, Blackmore CG, Dobbins AC, Varro A, Thompson DG, Dockray GJ: Mutations of regialpha are associated with enterochromaffin-like cell tumor development in patients with hypergastrinemia. Gastroenterology 1999;116 (6):1310–1318.

    Article  CAS  PubMed  Google Scholar 

  16. Burkitt MD, Pritchard DM: Review article: Pathogenesis and management of gastric carcinoid tumours. Aliment Pharmacol Ther 2006;24 (9):1305–1320.

    Article  CAS  PubMed  Google Scholar 

  17. D’Adda T, Keller G, Bordi C, Hofler H: Loss of heterozygosity in 11q13-14 regions in gastric neuroendocrine tumors not associated with multiple endocrine neoplasia type 1 syndrome. Lab Invest 1999;79 (6):671–677.

    PubMed  Google Scholar 

  18. Modlin IM, Lye KD, Kidd M: Carcinoid tumors of the stomach. Surg Oncol 2003;12 (2):153–172.

    Article  PubMed  Google Scholar 

  19. Jiao Y, Shi C, Edil BH, de Wilde RF, Klimstra DS, Maitra A, Schulick RD, Tang LH, Wolfgang CL, Choti MA, Velculescu VE, Diaz LA, Jr., Vogelstein B, Kinzler KW, Hruban RH, Papadopoulos N: Daxx/atrx, men1, and mtor pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 2011;331 (6021):1199–1203.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Chen SF, Kasajima A, Yazdani S, Chan MS, Wang L, He YY, Gao HW, Sasano H: Clinicopathologic significance of immunostaining of alpha-thalassemia/mental retardation syndrome x-linked protein and death domain-associated protein in neuroendocrine tumors. Hum Pathol 2013;44 (10):2199–2203.

    Article  CAS  PubMed  Google Scholar 

  21. Peny MO, Donckier V, Gelin M, Haot J, Noel JC: Sporadic carcinoid of the stomach: A highly proliferative disease with a probable role for p53 protein dysregulation. Eur J Gastroenterol Hepatol 1999;11 (6):677–679.

    Article  CAS  PubMed  Google Scholar 

  22. Rindi G, Bordi C, Rappel S, La Rosa S, Stolte M, Solcia E (1996) Gastric carcinoids and neuroendocrine carcinomas: pathogenesis, pathology, and behavior. World J Surg 20 (2):168–172

    Article  CAS  PubMed  Google Scholar 

  23. Bordi C, Falchetti A, Azzoni C, D’Adda T, Canavese G, Guariglia A, Santini D, Tomassetti P, Brandi ML (1997) Aggressive forms of gastric neuroendocrine tumors in multiple endocrine neoplasia type I. Am J Surg Pathol 21 (9):1075–1082

    Article  CAS  PubMed  Google Scholar 

  24. Bordi C, D’Adda T, Azzoni C, Pilato FP, Caruana P (1995) Hypergastrinemia and gastric enterochromaffin-like cells. Am J Surg Pathol 19 Suppl 1:S8–19

    PubMed  Google Scholar 

  25. Solcia E, Capella C, Fiocca R, Rindi G, Rosai J (1990) Gastric argyrophil carcinoidosis in patients with Zollinger-Ellison syndrome due to type 1 multiple endocrine neoplasia. A newly recognized association. Am J Surg Pathol 14 (6):503–513

    Article  CAS  PubMed  Google Scholar 

  26. Blank A, Wehweck L, Marinoni I, Boos LA, Bergmann F, Schmitt AM, Perren A: Interlaboratory variability of mib1 staining in well-differentiated pancreatic neuroendocrine tumors. Virchows Arch 2015;467 (5):543–550.

    Article  CAS  PubMed  Google Scholar 

  27. Basturk O, Yang Z, Tang LH, Hruban RH, Adsay V, McCall CM, Krasinskas AM, Jang KT, Frankel WL, Balci S, Sigel C, Klimstra DS (2015) The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms. Am J Surg Pathol 39 (5):683–690. doi:10.1097/pas.0000000000000408

    Article  PubMed  PubMed Central  Google Scholar 

  28. Tang LH, Untch BR, Reidy DL, O’Reilly E, Dhall D, Jih L, Basturk O, Allen PJ, Klimstra DS: Well-differentiated neuroendocrine tumors with a morphologically apparent high-grade component: A pathway distinct from poorly differentiated neuroendocrine carcinomas. Clin Cancer Res 2016;22 (4):1011–1017.

    Article  CAS  PubMed  Google Scholar 

  29. Sorbye H, Welin S, Langer SW, Vestermark LW, Holt N, Osterlund P, Dueland S, Hofsli E, Guren MG, Ohrling K, Birkemeyer E, Thiis-Evensen E, Biagini M, Gronbaek H, Soveri LM, Olsen IH, Federspiel B, Assmus J, Janson ET, Knigge U (2013) Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann Oncol 24 (1):152–160. doi:10.1093/annonc/mds276

    Article  CAS  PubMed  Google Scholar 

  30. Tang LH, Gonen M, Hedvat C, Modlin IM, Klimstra DS (2012) Objective quantification of the Ki67 proliferative index in neuroendocrine tumors of the gastroenteropancreatic system: a comparison of digital image analysis with manual methods. Am J Surg Pathol 36 (12):1761–1770. doi:10.1097/PAS.0b013e318263207c

    Article  PubMed  Google Scholar 

  31. Reid MD, Bagci P, Ohike N, Saka B, Erbarut Seven I, Dursun N, Balci S, Gucer H, Jang KT, Tajiri T, Basturk O, Kong SY, Goodman M, Akkas G, Adsay V (2015) Calculation of the Ki67 index in pancreatic neuroendocrine tumors: a comparative analysis of four counting methodologies. Mod Pathol 28 (5):686–694. doi:10.1038/modpathol.2014.156

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA

    Hee Eun Lee, Taofic Mounajjed, Lori A. Erickson & Tsung-Teh Wu

Authors
  1. Hee Eun Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Taofic Mounajjed
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lori A. Erickson
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tsung-Teh Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tsung-Teh Wu.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflicts of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lee, H.E., Mounajjed, T., Erickson, L.A. et al. Sporadic Gastric Well-Differentiated Neuroendocrine Tumors Have a Higher Ki-67 Proliferative Index. Endocr Pathol 27, 259–267 (2016). https://doi.org/10.1007/s12022-016-9443-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12022-016-9443-6

Keywords

Search

Navigation